Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NEPHROS INC (NEPH)
|
Add to portfolio |
|
|
|
| Price: |
$5.82
| | Metrics |
| OS: |
10.5
|
M
| |
-56
|
% ROE
|
| Market cap: |
$61
|
M
| |
-65
|
% ROIC
|
|
Net cash:
|
$4.06
|
M
| |
$0.39
|
per share
|
|
EV:
|
$57
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($2.7)
|
M
| |
|
|
|
EBIT
|
($2.7)
|
M
| |
|
|
| EPS |
($0.28)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 10.0 | 10.2 | 8.6 | 10.3 | 5.7 | 3.8 | 2.3 | 1.9 |
| Revenue growth | -2.4% | 19.3% | -17.2% | 81.7% | 49.3% | 64.2% | 19.3% | 11.2% |
| Cost of goods sold | 5.2 | 4.6 | 3.6 | 4.3 | 2.5 | 1.5 | 1.0 | 0.9 |
| Gross profit | 4.7 | 5.6 | 4.9 | 6.1 | 3.2 | 2.3 | 1.3 | 1.1 |
| Gross margin | 47.4% | 55.1% | 57.4% | 58.9% | 56.3% | 60.2% | 55.8% | 54.5% |
| Selling, general and administrative | 7.6 | 7.2 | 6.5 | 6.1 | 4.5 | 3.3 | 2.9 | 3.4 |
| Research and development | 1.3 | 1.5 | 2.8 | 3.1 | 1.5 | 1.0 | 1.1 | 0.8 |
| EBITA | -4.3 | -3.2 | -4.5 | -3.3 | -3.0 | -2.0 | -2.7 | -3.2 |
| EBITA margin | -43.0% | -31.4% | -52.1% | -31.6% | -53.0% | -53.5% | -114.6% | -165.1% |
| Amortization of intangibles | 0.0 | 0.0 | 0.0 | 0.0 | | 0.2 | 0.2 | 0.2 |
| EBIT | -4.3 | -3.3 | -4.5 | -3.3 | -3.0 | -2.2 | -2.9 | -3.4 |
| EBIT margin | -43.5% | -31.8% | -52.6% | -32.0% | -53.0% | -58.4% | -123.7% | -176.0% |
| Pre-tax income | -4.3 | -2.8 | -4.5 | -3.4 | -3.4 | -2.6 | -3.0 | -3.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | -0.2 | -0.1 | -1.8 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 6.6% | 2.7% | 68.9% | 0.0% | 0.0% |
| Earnings from continuing ops | -4.6 | -3.0 | -4.8 | -3.4 | -3.4 | -0.8 | -3.0 | -3.2 |
| Earnings from discontinued ops | -2.8 | -1.1 | | | | | | |
| Net income | -7.4 | -4.1 | -4.8 | -3.4 | -3.4 | -0.8 | -3.0 | -3.2 |
| Net margin | -74.0% | -40.2% | -55.7% | -33.1% | -59.8% | -21.2% | -130.7% | -162.6% |
| |
| Diluted EPS | ($0.44) | ($0.30) | ($0.52) | ($0.45) | ($0.50) | ($0.02) | ($0.06) | ($0.09) |
| Shares outstanding (diluted) | 10.3 | 10.0 | 9.1 | 7.5 | 6.8 | 52.9 | 48.6 | 34.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|